RecruitingNCT07004452

Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial


Sponsor

China National Center for Cardiovascular Diseases

Enrollment

5,000 participants

Start Date

Mar 31, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational cohort study is to establish a risk prediction model for adverse events in Chinese individuals under 45 years old with premature coronary artery disease. The main questions it aims to answer are: * What are the major risk factors for poor prognosis in Chinese patients with premature coronary artery disease? * What is the difference in the prognosis of patients with premature coronary heart disease with different phenotypes? Participants taking no mandatory intervention will be followed up for 2 year, with blood tests at 1 year and outpatient or telephone interviews at other timepoints.


Eligibility

Min Age: 18 YearsMax Age: 45 Years

Inclusion Criteria4

  • Age 18-45 years;
  • Clinically confirmed CAD with ≥50% luminal stenosis in at least one major coronary artery or significant branch, verified by coronary angiography;
  • For acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) patients: clinical stability meeting discharge criteria post-treatment;
  • Voluntary participation with signed informed consent.

Exclusion Criteria4

  • Heart transplant recipients;
  • Severe systemic comorbidities with life expectancy \<1 year;
  • Previous enrollment in other drug/device clinical trials without completing the primary endpoint observation period;
  • Inability to comply with follow-up (e.g., dementia, severe psychiatric disorders).

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

FuWai Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07004452


Related Trials